Therapeutics

400+ Companies
More info
Parent markets
Sibling markets
Related markets
400+ companies in Therapeutics
Show all
Amgen Inc.

Amgen Inc.

Manufacturing +2
Seattle Genetics

Seattle Genetics

Health Care +2
Ophelia

Ophelia

Health Care +2
Takeda

Takeda

Pharmaceuticals +1
Deep Genomics

Deep Genomics

Artificial Intelligence +2
Aimmune

Aimmune

Health and Wellness +2
Kaia Health

Kaia Health

Artificial Intelligence +2
Beam Therapeutics

Beam Therapeutics

Health Care +1
Cerevel Therapeutics

Cerevel Therapeutics

Biotechnology +1
Pear Therapeutics

Pear Therapeutics

Biotechnology +1
Xealth

Xealth

Personal Health +3
SilverCloud Health

SilverCloud Health

Enterprise Software +2
Moderna Therapeutics

Moderna Therapeutics

Biotechnology +1
Neuronetics, Inc.

Neuronetics, Inc.

Biotechnology +2
Aspen Neuroscience

Aspen Neuroscience

Medical +2
All companies in Therapeutics
Terms of Service Privacy Policy Cookie Statement
Built with ❤︎ by Datalicious ©2022
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

News

Funding rounds

Acquisitions

Companies

Investors

Filter companies
11 Nov 2021
Nuritas
Nuritas
$45,000,000
Venture capital (Series B)
Cultivian Sandbox Ventures, Wheatsheaf Group, Cleveland Avenue, +6

BREAKING: Nuritas raises $45 million to scale its plant-based peptides discovery platform

AFN
+1
03 Nov 2021
GRO Biosciences
GRO Biosciences
$25,000,000
Venture capital (Series A)
Redmile Group, Innovation Endeavors, Digitalis Ventures, +1

Synbio startup GRObio gets $25M to work with new building blocks for protein drugs

MedCity News
27 Oct 2021
Immunai
Immunai
$215,000,000
Venture capital (Series B)
Icon Ventures, Piedmont Capital, 8VC, +3

Immunai announces a $215M Series B as its ‘immune cell atlas’ matures

TechCrunch
25 Oct 2021
Click Therapeutics
Click Therapeutics
$52,000,000
Venture capital (Series B)
Accelmed, H.I.G. BioHealth Partners, Health Catalyst Capital, +5

Click Therapeutics raises $52M, looks to advance digital therapeutics

MedCity News
22 Oct 2021
Egle Therapeutics
Egle Therapeutics
€40,000,000
Venture capital (Series A)
Bpifrance, Life Sciences Partners, Fund+, +2

Already allied with Takeda, Egle raises €40M for its ‘starving’ immunotherapy

MedCity News
27 Sep 2021
Delix Therapeutics
Delix Therapeutics
$70,000,000
Venture capital (Series A)
RA Capital Management, Dolby Family Ventures, ARTIS Ventures, +15

Psychedelic drugs, but safer: Delix raises $70M to bring new neuro meds to clinic

MedCity News
23 Sep 2021
GenEdit Inc
GenEdit Inc
$26,000,000
Venture capital (Series A)
Sequoia Capital, IMM Investment, Korea Investment Partners, +7

Aiming for better genetic medicines delivery, startup GenEdit grabs $26M

MedCity News
13 Sep 2021
Walking Fish Therapeutics
Walking Fish Therapeutics
$50,000,000
Venture capital (Series A)
Emerson Collective, Illumina Ventures, Quan Capital

Startup Walking Fish nabs $50M to run with B cell therapies for cancer & more

MedCity News
09 Sep 2021
Neuroglee Therapeutics
Neuroglee Therapeutics
$10,000,000
Venture capital (Series A)
EDBI, Openspace Ventures, Ramen Singh, +3

Digital therapeutics startup Neuroglee raises $10M to help people with neurodegenerative conditions

TechCrunch
09 Sep 2021
DotCom Therapy
DotCom Therapy
$8,800,000
Venture capital (Series A)
New Capital Partners, OSF Ventures, LRVHealth

DotCom Therapy raises $13M to provide therapy for kids, in and out of school

TechCrunch
01 Sep 2021
Asher Bio
Asher Bio
$108,000,000
Venture capital (Series B)
RA Capital Management, Invus, Third Rock Ventures, +7

Asher Bio’s encouraging early data against rival cancer drug sparks $108M financing

MedCity News
31 Aug 2021
Alma
Alma
$50,000,000
Venture capital (Series C)
Insight Partners

Alma gets $50M to boost therapists’ practices

MedCity News